A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality

Weisdorf, 1990, Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome, Blood, 75, 1024, 10.1182/blood.V75.4.1024.1024 MacMillan, 2002, Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems, Biol Blood Marrow Transplant, 8, 387, 10.1053/bbmt.2002.v8.pm12171485 Martino, 1999, Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry, Bone Marrow Transplant, 24, 283, 10.1038/sj.bmt.1701899 Weisdorf, 2003, Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review, Biol Blood Marrow Transplant, 9, 512, 10.1016/S1083-8791(03)00162-9 Cahn, 2005, Blood, 106, 1495, 10.1182/blood-2004-11-4557 Levine, 2012, Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study, Blood, 119, 3854, 10.1182/blood-2012-01-403063 Vander Lugt, 2013, ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death, N Engl J Med, 369, 529, 10.1056/NEJMoa1213299 Levine, 2013, A biomarker-based grading system at onset of GVHD predicts TRM better than the modified Glucksberg Grading System, Blood, 122, 145, 10.1182/blood.V122.21.145.145 MacMillan, 2012, What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score, Br J Haematol, 157, 732, 10.1111/j.1365-2141.2012.09114.x Alousi, 2009, Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network, Blood, 114, 511, 10.1182/blood-2009-03-212290 Bolaños-Meade, 2014, Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802, Blood, 124, 3221, 10.1182/blood-2014-06-577023 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Lin, 1997, Non-parametric inference for cumulative incidence functions in competing risks studies, Stat Med, 16, 901, 10.1002/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M Cox, 1972, Regression models and life tables, J Royal Stast Soc, 34, 187 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 Breiman, 1984 Pencina, 2008, Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond, Stat Med, 27, 157, 10.1002/sim.2929 Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825 Rowlings, 1997, IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade, Br J Haematol, 97, 855, 10.1046/j.1365-2141.1997.1112925.x Weisdorf, 1990, Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy, Blood, 76, 624, 10.1182/blood.V76.3.624.624 Paczesny, 2013, Discovery and validation of graft-versus-host disease biomarkers, Blood, 121, 585, 10.1182/blood-2012-08-355990